ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Xencor earns $120 million from Genentech for IL-15 antibody

by Ryan Cross
February 8, 2019 | APPEARED IN VOLUME 97, ISSUE 6

 

Genentech will pay $120 million up front to partner with the antibody company Xencor on new cancer immunotherapies based on a protein called interleukin-15 (IL-15). Xencor’s lead program in the partnership combines IL-15 and its receptor, IL-15Rα, into a single protein designed to activate immune cells that can attack cancer. Xencor could receive up to $160 million more for developing the lead candidate and up to $180 million for each subsequent IL-15 drug.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment